Raymond James Financial
CTKB icon

Raymond James Financial’s Cytek Biosciences CTKB Stock Holding History

Raymond James Financial’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-117,870
Closed -$765K – 4840
2024
Q4 		$765K Buy
+117,870
New +$702K ﹤0.01% 3637

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial's CTKB Position: Q1 2025 in Review

Raymond James Financial sold out of Cytek Biosciences (CTKB) in Q1 2025, closing a stake of 117,870 shares — an estimated $765K sold.

Raymond James Financial first reported a position in CTKB in Q4 2024 and held it in 1 quarter. The position peaked at $765K in Q4 2024. 160 funds tracked by Wall St. Rank hold CTKB as of Q1 2025.

  • Raymond James Financial reported no remaining Cytek Biosciences position as of Q1 2025 after selling out during the quarter.
  • Raymond James Financial sold 117,870 Cytek Biosciences shares in Q1 2025, an estimated $765K.
  • Raymond James Financial first reported a position in Cytek Biosciences in Q4 2024 and held it in 1 quarter.
  • Raymond James Financial's Cytek Biosciences position peaked at $765K in Q4 2024.
  • 160 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2025.

Based on Raymond James Financial's 13F filing for Q1 2025, filed 13 May 2025.